We believe this portfolio offers the potential to reshape the treatment landscape, bring innovative products to patients and deliver attractive returns to our shareholders. Also in September, the European Medicines Agency approved Novo Nordisks oral semaglutide (Rybelsus), the first to reduce cardiovascular death, heart attack, and stroke, according to the companys website
But some patterns demand immediate attention
By aligning patient biology with drug discovery, Phenomix is shaping a more personalized and impactful future for obesity treatment
The practice of interventional cardiology includes several procedures aimed at opening the blood vessels and arteries and revascularizing the heart without performing major surgery
Novo looks to gain market share for weight-loss pill ahead of rival Lilly The approval could help spur a turnaround for the Danish pharmaceutical giant after a rocky year of sliding shares and slowing sales of its injectable Wegovy
I finally trust a weight loss clinic Palm Beach Gardens
